These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 9777131)
1. Alteplase (r-TPA) vs streptokinase. Hunt D Aust N Z J Med; 1998 Aug; 28(4):514-7. PubMed ID: 9777131 [TBL] [Abstract][Full Text] [Related]
2. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594 [TBL] [Abstract][Full Text] [Related]
3. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. Aylward PE; Wilcox RG; Horgan JH; White HD; Granger CB; Califf RM; Topol EJ Ann Intern Med; 1996 Dec; 125(11):891-900. PubMed ID: 8967669 [TBL] [Abstract][Full Text] [Related]
4. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective. Heyland DK; Gafni A; Levine MA J Clin Epidemiol; 2000 Sep; 53(9):888-94. PubMed ID: 11004415 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers. Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545 [TBL] [Abstract][Full Text] [Related]
6. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. White HD Am J Cardiol; 1998 Oct; 82(8B):57P-62P. PubMed ID: 9809893 [TBL] [Abstract][Full Text] [Related]
8. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators. Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216 [TBL] [Abstract][Full Text] [Related]
9. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780 [TBL] [Abstract][Full Text] [Related]
10. [Cardiovascular pharmacology (XIII). The efficacy of different thrombolytic drugs in the treatment of acute myocardial infarct]. López-Sendón J; López de Sá E; Bobadilla JF; Rubio R; Bermejo J; Delcán JL Rev Esp Cardiol; 1995 Jun; 48(6):407-39. PubMed ID: 9324694 [TBL] [Abstract][Full Text] [Related]
11. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. Singh N; Mironov D; Armstrong PW; Ross AM; Langer A Circulation; 1996 Apr; 93(7):1388-95. PubMed ID: 8641028 [TBL] [Abstract][Full Text] [Related]
12. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348 [TBL] [Abstract][Full Text] [Related]
13. [Thrombolysis in acute myocardial infarction. Streptokinase or r-TPA?]. Silva LA; Ribeiro E; Carneiro RC; Kaissar S; Reis Filho A; Torossian SP; Tavares JR; Buffolo E; Amino JG; Duprat Filho R Arq Bras Cardiol; 1990 Jul; 55(1):13-7. PubMed ID: 2127353 [TBL] [Abstract][Full Text] [Related]
14. Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Gillis JC; Wagstaff AJ; Goa KL Drugs; 1995 Jul; 50(1):102-36. PubMed ID: 7588083 [TBL] [Abstract][Full Text] [Related]
15. Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown. Gurewich V Cardiovasc Drugs Ther; 2019 Dec; 33(6):749-753. PubMed ID: 31897763 [TBL] [Abstract][Full Text] [Related]
16. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
17. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs. Tsui W; Pierre K; Massel D Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260 [TBL] [Abstract][Full Text] [Related]
18. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis. Hiatt MD Cardiology; 1999; 91(4):243-9. PubMed ID: 10545680 [TBL] [Abstract][Full Text] [Related]
19. Patency trials with reteplase (r-PA): what do they tell us? Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406 [TBL] [Abstract][Full Text] [Related]
20. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]